XTL Biopharmaceuticals (NASDAQ:XTLB) Stock Crosses Below 200-Day Moving Average – What’s Next?

Posted by Linda Flegge on May 19th, 2026

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB – Get Free Report)’s share price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $6.16 and traded as low as $2.56. XTL Biopharmaceuticals shares last traded at $2.6450, with a volume of 54,162 shares changing hands.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a report on Thursday, April 2nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, XTL Biopharmaceuticals has a consensus rating of “Sell”.

Get Our Latest Report on XTL Biopharmaceuticals

XTL Biopharmaceuticals Stock Performance

The stock has a market cap of $5.82 million, a price-to-earnings ratio of -4.13 and a beta of 1.64. The stock’s 50-day simple moving average is $2.61 and its two-hundred day simple moving average is $6.16.

XTL Biopharmaceuticals Company Profile

(Get Free Report)

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.